Skip to main content
TipRanks
Go Ultimate75% OFF

Evofem Biosciences (EVFM) AI Stock Analysis

1,208 Followers
EVFM

Evofem Biosciences

(Other OTC:EVFM)

Select Model
Rating:43Neutral
Price Target:$0.01â–²(57.48% Upside)
Action:reiterated
Date:11/14/26

The score is driven down primarily by weak financial performance—shrinking TTM revenue, deeply negative profitability, ongoing negative cash flow, and a highly stressed balance sheet with negative equity and meaningful debt. A positive manufacturing expansion event provides some operational upside, but valuation is constrained by negative earnings and technical signals are largely unavailable, limiting support for a higher score.

Positive Factors
Gross MarginThe approximately 69% TTM gross margin indicates that Phexxi generates relatively strong product-level economics before operating expenses. If revenue stabilizes and spending becomes more disciplined, this margin profile could support improved operating leverage and a more sustainable commercial model.
Negative Factors
Revenue and ProfitabilityThe sharp TTM revenue decline alongside a near negative 98% net margin shows that commercial scale and earnings durability remain unproven. Even with strong gross margins, continued operating losses make results highly sensitive to expense levels and weaken the company’s ability to fund growth internally.

Evofem Biosciences (EVFM) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%EVFM0.00%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$801.81K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.1
Beta (1Y)
0.32
Revenue Growth
-0.03%
EPS Growth
-88.76%
Country
US
Employees
29
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Evofem Biosciences Business Overview & Revenue Model

Company Description

Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phex...

Evofem Biosciences Financial Statement Overview

Summary

Financials are very weak overall: TTM revenue declined sharply (-27.4%), profitability deteriorated to deeply negative (near -98% net margin), and operating/free cash flow remain negative. The balance sheet is the largest risk with persistent negative equity (TTM about -$78.8M) and sizable debt (about $70.4M) versus a very small asset base, implying elevated financing/dilution risk despite relatively strong gross margins (~69%).

Income Statement

34Negative

Balance Sheet

18Very Negative

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Mar 2023Dec 2021
Income Statement
Total Revenue17.72M20.18M19.36M18.22M16.84M8.24M
Gross Profit12.94M15.07M15.53M11.71M12.42M4.19M
EBITDA-2.66M2.06M-6.92M-16.07M-82.08M-165.78M
Net Income-12.73M391.00K-8.86M52.98M-76.70M-205.19M
Balance Sheet
Total Assets7.26M20.27M23.79M10.55M25.16M42.51M
Cash, Cash Equivalents and Short-Term Investments317.00K578.00K741.00K580.00K2.77M7.73M
Total Debt70.39M54.55M45.97M43.37M71.13M115.68M
Total Liabilities86.02M89.71M95.05M77.06M96.96M142.09M
Stockholders Equity-78.76M-69.44M-71.26M-66.51M-71.80M-99.58M
Cash Flow
Free Cash Flow-599.00K-2.00M-3.90M-8.97M-70.75M-149.61M
Operating Cash Flow-594.00K-1.99M-3.88M-8.97M-70.41M-146.67M
Investing Cash Flow-5,000-62.00K-569.00K-4,000-341.00K-2.69M
Financing Cash Flow76.00K1.89M4.62M4.78M61.94M90.69M

Evofem Biosciences Risk Analysis

Evofem Biosciences disclosed 87 risk factors in its most recent earnings report. Evofem Biosciences reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Evofem Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

EVFM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PTNPTN46Neutral$10.91M-1.15-115.00%―-46.89%55.46%
LPCNLPCN45Neutral$18.38M-1.24-46.52%―-13.37%-33.44%
EVFMEVFM43Neutral$801.81K-0.0616.78%―-0.03%-88.76%
DAREDARE38Underperform$11.49M-0.77-748.08%―――

* Healthcare Sector Average

Performance Comparison

0%100%200%EVFMPTNDARELPCNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
EVFM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
EVFMEvofem Biosciences, Inc.0.010.000.00%
PTNPalatin Technologies, Inc.6.13-7.68-55.62%
DAREDaré Bioscience0.58-1.13-65.85%
LPCNLipocine Inc1.66-1.55-48.29%

Evofem Biosciences Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Evofem amends key convertible note financing terms

Neutral
Oct 15, 2026

On October 9, 2026, Evofem Biosciences, Inc. and Adjuvant Global Health Technology Fund entered into a fifth amendment to their October 14, 2020 Securities Purchase Agreement governing certain convertible promissory notes. The amendment extends and c...

Business Operations and StrategyProduct-Related Announcements

Evofem Expands PHEXX Manufacturing Capacity for Global Growth

Positive
Sep 23, 2026

On September 17, 2026, Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical entities in Hong Kong and Guangzhou to add them as a producer and supplier of PHEXX, its hormone-free contraceptive gel. The mov...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026